Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA) for Haplo-Cord Transplantation

What's the purpose of this trial?

In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes. We hypothesize that identification of a graft that is at least 5/6 matched and inherited paternal antigen (IPA) targeted (i.e., cord blood grafts share one or more IPA antigens with the prospective recipient) is more important to the outcome of haplo cord transplant than the nucleated cell dose.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Subject must have a confirmed diagnosis of:
    1. Previously Relapsed or refractory acute leukemia (myeloid or lymphoid)
    2. Acute leukemia in first remission at high-risk for recurrence
    3. Chronic myelogenous leukemia in chronic, accelerated phase or blast-crisis
    4. Recurrent or refractory malignant lymphoma or Hodgkin lymphoma
    5. Chronic lymphocytic leukemia, relapsed or with poor prognostic features
    6. Multiple myeloma
    7. Myelodysplastic syndrome
    8. Chronic myeloproliferative disease
    9. Hemoglobinopathies
    10. Aplastic anemia
    11. Other hematological disorder in need of allogeneic transplant (e.g. blastoid dendritic cell neoplasm)
  • Age ≥ 18 years
  • Likely to benefit from allogeneic transplant in the opinion of the transplant physician
  • An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame.
  • Karnofsky (KPS) Performance status of >= 70%
  • Acceptable organ function as defined below: Serum bilirubin: < 2.0mg/dL ALT(SGPT): < 3 X upper limit of normal Creatinine Clearance: > 50 mL/min/1.73m2 (as estimated by the modified MDRD equation)
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Life expectancy is severely limited by concomitant illness or uncontrolled infection
  • Severely decreased Left Ventricular Ejection Fraction (LVEF) or impaired pulmonary function tests (PFT's)
  • Evidence of chronic active hepatitis or cirrhosis
  • Uncontrolled HIV disease
  • Pregnant or lactating

Additional Trial Information

Phase 2

Enrollment: 500 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Illinois

University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

Open and Accepting

New York

Weill Cornell

New York, NY

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message